journal articles
THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ON
J.C.S. Breitner, C.G. Lyketsos
J Prev Alz Dis 2014;1(3):176-180
The Alzheimer’s Disease Anti-inflammatory Prevention Trial
was a placebo-controlled three-arm pharmaco-prevention trial
of the non-steroidal anti-inflammatory drugs naproxen sodium
and celecoxib for prevention of incident Alzheimer’s disease
(AD) dementia in older (aged 70 and over) adults. Although
subjects were at increased risk of symptoms because of a firstdegree
family history, they were meant to be cognitively
healthy at enrollment. ADAPT encountered several problems
that resulted in the termination of its treatments after only two
years on average. Interim results were complex but potentially
interesting. In the end, however, the results were null. We
describe the complications that prevented ADAPT from
achieving conclusive results, and suggest that these could have
been avoided if the trial design and execution had been better
guided by preliminary data. We believe such data should be
available before beginning further ambitious phase III trials of
this sort, and we suggest a broad method by which such data
can be accumulated with reasonable economy.
CITATION:
J.C.S. Breitner ; C.G. Lyketsos (2014): THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ON. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2014.31